Serum concentration of baseline mast cell tryptase: Evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy

Clinical and Experimental Allergy

Volumn 40, Issue 4, 2010, Pages 643-649

  Dugas Breit, S ^a   Przybilla, B ^a   Dugas, M ^b   Arnold, A ^a   Pfundstein, G ^c   Kuchenhoff H ^c   Rueff F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Age; Hymenoptera venom allergy; Mastocytosis; Serum mast cell tryptase concentration; Venom immunotherapy

Indexed keywords

HYMENOPTERA VENOM; TRYPTASE;

ADULT; ALLERGY; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); FEMALE; GENDER; HOSPITAL; HUMAN; HYMENOPTERA; HYMENOPTERA VENOM ALLERGY; IMMUNOTHERAPY; INSECT STING; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAST CELL; NONHUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANIMALS; BEE VENOMS; BEES; CHILD; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYMENOPTERA; HYPERSENSITIVITY, IMMEDIATE; INSECT BITES AND STINGS; MALE; MAST CELLS; MASTOCYTOSIS; MIDDLE AGED; TIME FACTORS; TRYPTASES; WASP VENOMS; WASPS; YOUNG ADULT;

EID: 77949355609     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03436.x     Document Type: Article

References (34)

1. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316:1622-6.
2. van der Linden PW, Hack CE, Poortman J, Vivié-Kipp YC, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation. J Allergy Clin Immunol 1992; 90:110-8.
3. Schwartz LB, Min HK, Ren S et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol 2003; 170:5667-73.
4. Min HK, Moxley G, Neale MC, Schwartz LB. Effect of sex and haplotype on plasma tryptase levels in healthy adults. J Allergy Clin Immunol 2004; 114:48-51.
5. Akin C, Soto D, Brittain E et al. Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels. Clin Immunol 2007; 123:268-71.
6. Schwartz LB, Bradford TR, Rouse C et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14:190-204.
7. Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989; 83:1551-5.
8. Sperr WR, Jordan JH, Fiegl M et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002; 128:136-41.
9. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin N Am 2006; 26: 451-63.
10. Klion AD, Noel P, Akin C et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660-6.
11. Ludolph-Hauser D, Ruëff F, Fries C, Schöopf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361-2.
12. Haeberli G, Brönnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216-20.
13. Kucharewicz I, Bodzenta-Lukaszyk A, Szymanski W, Mroczko B, Szmitkowski M. Basal serum tryptase level correlates with severity of hymenoptera sting and age. J Invest Allergol Clin Immunol 2007; 17:65-9.
14. Ring J, Meßmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1:466-9.
15. Valent P, Horny HP, Escribano L et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukocyte Res 2001; 25:603-25.
16. Bonadonna P, Perbellini O, Passalacqua G et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680-6.
17. Przybilla B, Müller U, Jarisch R, Ruëff F. Erhöhte basale Serum-tryptasekonzentration oder Mastozytose als Risikofaktor der Hymenopterengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergol J 2004; 13:440-2.
18. Jones I, Petersen GB. Normal day to day variation of tryptase in serum. Allergy 2000; 55 (Suppl. 59):214-5.
19. Dugas-Breit S, Przybilla B, Schöpf P, Ruëff F. Possible circadian variation of serum mast cell tryptase concentration. Allergy 2005; 60:689-92.
20. Schwartz LB. Mast cells and basophils. Clin Allergy Immunol 2002; 16:3-42.
21. Maurer M, Theoharides T, Granstein RD et al. What is the physiological function of mast cells? Exp Dermatol 2003; 12:886-910.
22. Hidvégi B, Nagy E, Szabó T et al. Correlation between T-cell and mast cell activity in patients with chronic urticaria. Int Arch Allergy Immunol 2003; 132:177-82.
23. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003; 139:1577-82.
24. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111:743-9.
25. Cooper PJ, Schwartz LB, Irani AM, Awadzi K, Guderian RH, Nutman TB. Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin. J Infect Dis 2002; 186:1307-13.
26. Lange L, Rietschel E, Hunzelmann N, Hartmann K. Elevated levels of tryptase in children with nummular eczema. Allergy 2008; 63:947-9.
27. Deliargyris EN, Upadhya B, Sane DC et al. Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. Atherosclerosis 2005; 178:381-6.
28. Lindstedt KA, Mäyränpää MI, Kovanen PT. Mast cells in vulnerable atherosclerotic plaques - a view to a kill. J Cell Mol Med 2007; 11:739-58.
29. Fairweather D, Frisancho-Kiss S. Mast cells and inflammatory heart disease: potential drug targets. Cardiovasc Hematol Disord Drug Targets 2008; 8:80-90.
30. Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 2009; 10:73-86.
31. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009; 123:735-46.
32. Speiran K, Bailey DP, Fernando J et al. Endogenous suppression of mast cell development and survival by IL-4 and IL-10. J Leukocyte Biol 2009; 85:826-36.
33. Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller UEAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70.
34. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120 (Suppl. 3):S25-85.